John Geisler, Ph.D. Email & Phone Number

John Geisler, Ph.D. is a Founder & CSO at Mitochon Pharmaceuticals, Inc. based in Spring House, Pennsylvania, United States, North America. Founder and Chief Scientific Officer of Mitochon Pharmaceuticals, Inc., focused on the development of “disease modifying” therapies to treat a host of time sensitive insidious diseases by modulating mitochondrial physiology to change dysfunctional organelles back to a normal healthy population and thereby resolving predominant manifestations of the disease. Expertise stems from over 20-years experience in Drug Discovery as a pharmacologist, physiologist and mammalian geneticist involved in the inception of ideas to resolve Metabolic Disease, which carried over into neurodegenerative/neuromuscular applications. Since most, if not all neurodegenerative diseases are associated with mitochondrial dysfunction, and the tool box for diabetes is comparatively excellent, I shifted my focus. Mitochon was launched in 2014 to determine if a mitochondrial approach has merit to treat diseases associated with neurodegeneration, autoimmune, neuromuscular and development disorders. The preclinical data says overwhelming Yes. Now, we are in the clinic to prove translation with an FDA granted open IND.